ClinicalTrials.gg

Prostatic Neoplasms, Castration-Resistant clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 85 studies for Prostatic Neoplasms, Castration-Resistant across more than 10 countries. 28 are recruiting or about to start. 73 of them are mainly about Prostatic Neoplasms, Castration-Resistant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
26
Recruiting
25
Terminated
11
Active, not recruiting
10
Withdrawn
5
Status unknown
3

Phase

Phase 1
33
Phase 2
30
Phase 3
10
Phase 4
3
Early Phase 1
1

Where

United States
50
Spain
21
France
19
Australia
19
United Kingdom
18
Italy
13

Who develops what

Add Prostatic Neoplasms, Castration-Resistant to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 5 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Johnson & Johnson, Merck and Novartis here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
enzalutamideRecent, repeated
Evidence
  • NCT06863272 · Merck & Co., Inc · Phase 2 · live · background · “Enzalutamide” · registered Mar 2025
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
  • NCT05191017 · Nuvation Bio Inc. · Phase 2 · background · “Enzalutamide” · registered Dec 2021
  • NCT04844749 · Veru Inc. · Phase 3 · comparator · “Enzalutamide, Abiraterone” · registered Apr 2021
  • NCT04104776 · Novartis · Phase 2 · live · background · “Enzalutamide” · registered Sep 2019
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized33 studies
PrednisoneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07225946 · Johnson & Johnson · Phase 3 · live · comparator · “Prednisone/Prednisolone” · registered Nov 2025
  • NCT06353386 · Merck & Co., Inc · Phase 2 · live · background · “Prednisone” · registered Apr 2024
  • NCT05848011 · MacroGenics · Phase 2 · background · “Prednisone” · registered Apr 2023
  • NCT03748641 · Johnson & Johnson · Phase 3 · live · background · “Prednisone” · registered Nov 2018
  • NCT03431350 · Johnson & Johnson · Phase 2 · live · background · “Prednisone 5 mg” · registered Feb 2018
Johnson & Johnson11% of its industry studies33 studies
DocetaxelRecent, repeated
Evidence
  • NCT07225946 · Johnson & Johnson · Phase 3 · live · background · “Docetaxel” · registered Nov 2025
  • NCT06863272 · Merck & Co., Inc · Phase 2 · live · comparator · “Docetaxel” · registered Mar 2025
  • NCT06353386 · Merck & Co., Inc · Phase 2 · live · background · “Docetaxel” · registered Apr 2024
  • NCT05848011 · MacroGenics · Phase 2 · background · “docetaxel” · registered Apr 2023
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized34 studies
Abiraterone AcetateRecent, repeated
Evidence
  • NCT06863272 · Merck & Co., Inc · Phase 2 · live · background · “Abiraterone” · registered Mar 2025
  • NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
  • NCT04844749 · Veru Inc. · Phase 3 · comparator · “Enzalutamide, Abiraterone” · registered Apr 2021
Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized22 studies

5 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
pasritamig☆ Track2 live phase-3 studies: NCT07225946, NCT07164443Johnson & Johnson
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401☆ Track1 live phase-3 study: NCT07164443Johnson & Johnson

The 2 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 16 Jul 2027 est.luxdegalutamide · Novartis · Phase 2 main aimNCT07047118 A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) — primary endpoint: Prostate Specific Antigen 50 (PSA50) Rate · 138 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Prostatic Neoplasms, Castration-Resistant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiandrogens 2 open · Immune checkpoint inhibitors 7 · Antimitotic agents 5

Coming up

11studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (4%) take children under 18. 0 (0%) are for women only and 20 (80%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
100 (0%)1 (4%)
185 (20%)25 (100%)
305 (20%)25 (100%)
405 (20%)25 (100%)
505 (20%)25 (100%)
655 (20%)25 (100%)
755 (20%)25 (100%)
855 (20%)25 (100%)

Across all 85 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 6% take children; 0% are for women only and 82% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 85. Browse all 85 → or search them.